Clinical Trials
25 trialsNCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01226394 2026-04-06
ProphyloCHIP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT06839092 2025-07-30
PROPAC
University Hospital, Geneva
Phase 3 Not yet recruiting
NCT03348150 2025-07-17
PERISCOPEII
The Netherlands Cancer Institute
Phase 3 Active not recruiting
NCT05257408 2025-04-16
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
Phase 3 Active not recruiting
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT01462890 2022-07-20
BOOST
AGO Study Group
Phase 3 Completed
NCT02231086 2021-09-16
COLOPEC
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Completed
NCT02158988 2021-07-29
GASTRIPEC
Charite University, Berlin, Germany
Phase 3 Completed
NCT00262990 2020-12-17
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
Phase 3 Completed
NCT00216372 2020-11-05
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
Ipsen
Phase 3 Completed
NCT04370925 2020-06-16
Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT02681432 2018-08-21
hipecova
Hospital General de Ciudad Real
Phase 3 Unknown
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT02840331 2017-10-27
Hypericin-PDT
University Hospital Tuebingen
Phase 3 Unknown
NCT03221608 2017-07-18
Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT03179579 2017-06-07
Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3 Unknown
NCT00769405 2016-08-30
Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer
UNICANCER
Phase 3 Completed
NCT00382811 2016-07-18
OVATURE
MEI Pharma, Inc.
Phase 3 Completed
NCT00191646 2011-03-04
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT00191607 2007-01-26
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
Phase 3 Completed